Skip to content
Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Anjalee Khemlani speak with Sorrento Therapeutics CEO & Founder Dr. Henry Ji about the company's FDA clearance for a COVID-19 drug trial, to be used on patients with milder symptoms. ...
Driveri has mapped data from vehicles traveling more than 1 billion miles on U.S. roads, including 1.8 million unique miles. ...
Moleculin Biotech (MBRX) on Tuesday announced that a second round of independent laboratory testing has confirmed the antiviral activity of its drug candidate WP1122 as a potential treatment against coronavirus. The news is pushing shares up 33% to $1.46 in early market trading.Moleculin said that it contracted with IIT Research Institute for additional in vitro testing of its WP1122. The testing involved a cell viability assay in the VERO E6 cell line infected with SARS-CoV-2 and compared the therapeutic effects of 2-deoxy-D-glucose or 2-DG (the active ingredient in WP1122) alone with those of WP1122, a 2-DG prodrug. Results of a previous test earlier this year, showed that 2-DG reduced the virus that causes COVID-19 by 100% in in vitro testing."Having validation in yet another virus host cell line provides additional confidence in the antiviral activity we are seeing,” said Moleculin CEO Walter Klemp. “We are also gaining confidence that in vitro testing results...
Despite COVID-19's devastating impact on the economy, Goldman Sachs’ chief U.S. equity strategist David Kostin believes 2020 earnings might not be as bad as previously expected. Kostin gave his estimate for S&P 500 earnings per share in 2020 a lift, from $110 to $115. For 2021, the forecast remains at $170, which is 4% above 2019’s realized level, with the figure landing at $188 for 2022.That said, management commentary will be an essential factor in gauging the outlook. “Given the heightened investor focus on the earnings outlook in 2021 and 2022, we expect management commentary will prove more valuable than backward-looking results,” Kostin wrote in a recent note.As for his stock picks, the strategist argues that given the low interest rate environment, names with the longest-duration cash flow are “what you want to own.” These companies include those in the technology and healthcare sectors.Bearing this in mind, we used TipRanks’ database...
D. Jordan became the CEO of First Horizon National Corporation (NYSE:FHN) in 2008, and we think it's a good time to......
Does the July share price for OPKO Health, Inc. (NASDAQ:OPK) reflect what it's really worth? Today, we will estimate......
